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Abstract
The antiphospholipid antibodies (aPL) are commonly associated with thrombotic 
events and obstetric complications. However, apart from the bleeding complications 
of antithrombotic therapy, the acquired coagulopathy caused by the aPL, particu-
larly by lupus anticoagulant and anticardiolipin antibodies, might be occasionally 
manifested as a hemorrhagic syndrome with various clinical severity. Bleeding 
symptoms vary from mild (mucocutaneous) up to life-threatening (gastrointestinal, 
intracranial). The bleeding may be the first manifestation of aPL or appear concomi-
tantly with thrombosis. The underlying hemostatic changes include thrombocyto-
penia, platelet function disorders, and coagulation factor inhibitors or deficiencies, 
namely prothrombin, FVII, FVIII, FX, and FXI. Thrombocytopenia is the most 
common finding, seen in up to 53% of patients with aPL, although it is usually mild 
to moderate and associated with significant bleeding only in a minority of cases. 
Of interest, patients with severe thrombocytopenia appear to be less likely to suffer 
from thrombotic events. The involved pathophysiological mechanisms are heteroge-
neous. Non-neutralizing antibodies against coagulation factors resulting in increased 
clearance, specific antibodies against platelet membrane glycoproteins, increasing 
platelet activation and aggregation with subsequent consumption, and immune-
mediated platelet clearance are among those identified. Immunosuppression, 
preferably with corticosteroids, represents the first-choice therapeutic approach. 
Plasmapheresis is efficient in the case of catastrophic antiphospholipid syndrome. 
Antithrombotic therapy can be challenging, but its administration should continue 
as much as possible.
Keywords: hemorrhage, antiphospholipid antibodies, thrombocytopenia,  
acquired prothrombin deficiency, acquired coagulation factor deficiencies, 
coagulation factor inhibitors
1. Introduction
The antiphospholipid syndrome (APS) is an acquired autoimmune disorder, 
defined by the combination of generally accepted laboratory and clinical criteria 
[1]. The latest laboratory criteria include repeated (at least 12 weeks apart) posi-
tive testing for at least 1 of 3 selected antiphospholipid antibodies (aPL): lupus 
anticoagulant (LA), anticardiolipin (aCL), anti-beta2-glycoprotein I (anti-B2GPI) 
antibodies. Clinical criteria emphasize the arterial and venous thromboembolic 
and pregnancy-related (recurrent miscarriages in the first trimester, fetal death 
in the second or third trimesters, severe pre-eclampsia requiring delivery of a 
premature infant before 34 weeks of gestation) events. However, other laboratory 
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and clinical complications with clear association to aPL, referred to as non-criteria 
manifestations, have been described. Based on the affected organ system, the 
clinical non-criteria manifestations divide into several subgroups: cardiovascular, 
neurologic, skin, renal, hematologic, and other [2, 3]. Hematologic complications 
include thrombocytopenia, hemolytic anemia, and functional changes or deficien-
cies of coagulation factors with both thrombotic (acquired resistance to activated 
protein C, protein S deficiency) or bleeding tendencies. As mentioned above, 
the association of aPL with thromboembolic events is extensively and well docu-
mented. However, the acquired coagulopathy caused by the aPL is complex and 
Figure 1. 
Pathomechanisms involved in hemorrhage in aPL patients. CAPS, catastrophic antiphospholipid syndrome; 
DIC, disseminated intravascular coagulation; F, factor; vWF, von Willebrand factor; * most common 
pathomechanisms.
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might occasionally manifest as a hemorrhagic event with various clinical severity or 
combined thrombo-hemorrhagic syndrome. The latter is common in catastrophic 
APS (CAPS), a rare but often fatal variant with excessive activation of hemostasis, 
consumption of its components, and micro-thrombotic damage in multiple organs.
aPL can interact with different blood and vascular components and cause hem-
orrhage through several mechanisms (Figure 1) [1]. Firstly, aPL-positive patients 
frequently develop thrombocytopenia. Secondly, acquired immune-mediated 
coagulation factor deficiencies, such as hypoprothrombinemia, can appear after the 
interaction between aPL and coagulation factors.
Thirdly, the microvascular system damage with an extensive thrombotic or 
inflammatory insult via the monocyte, endothelial, and complement activation can 
result in secondary bleeding to the affected tissue. Thrombotic microangiopathies 
(TMAs) such as CAPS, as well as diffuse alveolar hemorrhage (DAH) and adrenal 
hemorrhage (AH), the pathognomic complications of APS, are representative 
examples of this pathomechanism. Since the antithrombotic therapy remains a 
mainstay of management of aPL, the extensive use of antithrombotics, typical for 
patients afflicted with their presence, can contribute to bleeding events and repre-
sents the fourth cause. Severe thrombocytopenia (platelet count lower than 50000/
μL) and prothrombin deficiency are the most prominent causes of bleeding [4]. The 
discussion of the given pathomechanisms follows.
2. Thrombocytopenia in patients with aPL
Though not included in the current diagnostic criteria for APS (Sydney 2012 
criteria), thrombocytopenia represents a complication directly linked to aPL [1]. 
Thrombocytopenia is a frequent finding in aPL-positive patients; it is their most 
common non-criteria hematologic manifestation. The Euro-Phospholipid project, 
a large prospective multicenter international study evaluating 1000 European 
patients with both primary and secondary APS, found thrombocytopenia in 296 
(29.6%) of its participants [5]. Other studies focused on the whole population of 
aPL-positive patients reported comparable incidence, ranging from 20 to 53% 
[6–10]. Of interest, particular subgroups seem to be more prone to develop throm-
bocytopenia. Patients with secondary APS associated with systemic lupus erythe-
matosus (SLE) have thrombocytopenia approximately 2-times more often than 
those with primary APS (reported incidence 40 vs. 21% in the Euro-Phospholipid 
project) [5]. A low platelet count is more frequent in patients with CAPS [10, 11].
Thrombocytopenia tends to be mild to moderate with the nadir above 50000/μL 
in most cases. Only a small portion of patients (approximately 10%) develop severe 
thrombocytopenia, and its occurrence is often associated with other complications, 
such as TMAs (disseminated intravascular coagulation (DIC), CAPS) [8]. Rapid 
(within days) progression of thrombocytopenia or its new occurrence in patients 
with previously normal platelet count can be the first indication of CAPS [11, 12].
Despite being common, thrombocytopenia alone is not usually responsible 
for clinically relevant bleeding. For example, in the Italian Registry of aPL, only 
four patients out of 90 with thrombocytopenia experienced major hemorrhagic 
events [8]. On the other hand, nor it protects, especially if mild to moderate, from 
thromboembolism. Notwithstanding, if severe and without CAPS, it can account 
for a minor protective effect. In the Italian Registry with 360 patients included, 
severe thrombocytopenia was associated with a significantly lower rate of throm-
botic events in comparison to the group with normal platelet count; however, the 
group with mild thrombocytopenia did not show a significant difference (9 vs. 
40 vs. 32%) [8]. A recent study analyzing altogether 305 patients with primary 
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APS, 51 with thrombocytopenia included, observed a higher rate of thrombotic 
relapses (29% vs. 19%) during a long (median 11 years) follow-up in the group with 
thrombocytopenia, though the difference did not reach statistical significance [13]. 
Despite comparable antithrombotic therapy, no difference in major hemorrhage 
(4% vs. 3%) was observed between the thrombocytopenic and non-thrombocy-
topenic group, albeit the significantly higher rate of overall bleeding (17% vs. 8%) 
was in the thrombocytopenic group. The authors conclude that thrombocytopenia 
may have a prognostic value in primary APS and help identify high-risk patients for 
APS-related complications [13].
The evidence concerning the association between thrombocytopenia and 
other clinical features of APS such as hemolytic anemia, livedo reticularis, skin 
ulcerations, chorea, and cardiac valve dysfunction is conflicting. Some studies, but 
not all, observed more frequent occurrence of those symptoms in patients with 
thrombocytopenia.
The pathogenesis of aPL-related thrombocytopenia is likely heterogeneous. 
aPL can directly or indirectly via B2GPI interact with several platelet membrane 
glycoproteins (GP) and phospholipids and thus initiate two processes: 1) pathologi-
cally enhanced platelet activation and aggregation after their initial activation or 
damage with subsequent platelet thrombus formation and platelet consumption; 
2) immune-mediated pathological platelet clearance. The interaction with platelets 
involves the binding of anti-B2GPI via B2GPI to the activated platelet surface or 
direct interaction of aPL with specific platelet membrane glycoproteins (GPIb/IX, 
GPIIb/IIIa, GPIV) [14]. Particular subtypes of aPL and their quantity likely play a 
prominent role in the pathogenesis of thrombocytopenia. Anti–B2GPI antibodies 
of IgG class, LA, a higher titer of aCL of IgG class, and triple aPL positivity were 
a more common finding in patients with thrombocytopenia [13, 15, 16]. LA and 
a high titer of aCL were frequent among patients with severe thrombocytopenia. 
Since LA is associated with the highest prothrombotic risk among aPL, its higher 
prevalence in these patients could mitigate the bleeding tendencies and contribute 
to a relatively low rate of major bleedings.
Other pathomechanisms may occasionally contribute to thrombocytopenia in 
aPL-positive patients. The association, albeit anecdotal, between aPL and the hemo-
phagocytic syndrome (a hyperinflammatory disorder with pathological phagocy-
tosis of blood cells and their precursors in the bone marrow and other tissues) and 
bone marrow necrosis was described [17, 18]. These disorders decrease platelets via 
impairing megakaryopoiesis. Splenomegaly after splenic or portal vein thrombosis 
leads to increased platelet pooling and redistribution from circulation [7].
It should be emphasized that the etiology of thrombocytopenia in aPL-positive 
patients can be multifactorial and not exclusively linked to these antibodies. 
Other diseases can contribute to and further deepen the decrease in platelet count. 
Coincidence with immune thrombocytopenia (ITP), drug-induced thrombocy-
topenia with heparin-induced thrombocytopenia included, thrombocytopenia 
related to infections, TMAs, and pregnancy-related thrombocytopenia have been 
described [18, 19].
The relationship with ITP seems to be particularly interesting and complex. 
Patients with ITP are frequently positively tested for aPL, with a reported incidence 
ranging from 25 to 75% [20]. A recent retrospective study of 159 adult patients 
with primary and secondary severe ITP (platelet count below 50000/μL) identified 
aPL in 37 (23.2%), with 14 being triple positive. Triple positivity was associated 
with a lower platelet count [21]. Clinical implications of the relation between ITP 
and aPL are still discussed and not clear. The available data regarding the risk of 
thrombosis and treatment are inconclusive. However, a recent study with altogether 
196 patients with primary ITP, 49 aPL-positive included, did observe a significantly 
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higher risk of thrombotic events. Other monitored characteristics (hemorrhage, 
response to therapy, clinical course, changes in platelet counts) were comparable 
[19]. Analogically to the observation in APS, it seems that the risk of thrombosis in 
patients with concomitant ITP and aPL positivity, particularly in those undergoing 
therapy with corticosteroids and other immunosuppressive agents, is more promi-
nent than the risk of bleeding.
The diagnostic approach has to consider the possibility of aPL as a sole cause of 
thrombocytopenia as well as the coincidence of other disorders with aPL, especially 
TMAs. Since patients with aPL/APS are often anticoagulated and treated with 
immunosuppressives, heparin-induced thrombocytopenia and infectious causes 
should be addressed in the diagnostic process.
Since thrombocytopenia in aPL-positive patients is predominantly mild and 
without significant bleeding, outside of CAPS, most patients do not require specific 
treatment. As a general rule, the goal is to maintain the platelet count above 30000/
μL – a critical threshold for the development of severe spontaneous bleeding. 
When immune etiology is behind thrombocytopenia, strategies effective in ITP 
are preferably used [22, 23]. Corticosteroids, initially in high-dose with gradual 
tapering, alone or combined with intravenous immunoglobulins (IVIg), represent 
the first-line treatment. In contrast to ITP, the use of IVIg as a first-line treatment 
is controversial in aPL-positive patients since their administration is potentially 
associated with an increased risk of thrombotic events [24]. Other immunosuppres-
sive or immunomodulatory agents or procedures (danazol, chloroquine, dapsone, 
rituximab, plasmapheresis) or splenectomy can be chosen as alternatives for those 
with inadequate response. Rituximab seems to be a particularly perspective agent. 
Though only limited clinical data from a small number of patients are available 
so far, the response and persisting stable platelet count after rituximab have been 
observed in a reasonably high number (50–83%) of treated patients [25, 26]. It is 
important to emphasize that most of the included patients had refractory throm-
bocytopenia without a satisfactory response to previous treatment modalities. 
Rituximab was tolerated well with no significant increase in thrombotic risk. Its risk 
profile in the aPL setting appears to be comparable to ITP [25].
The use of thrombopoietin mimetics (TPOMs) remains controversial due to 
the conflicting clinical data. There is a general agreement on their effectiveness 
in increasing platelet count, but safety remains an open issue. Several authors did 
not observe any increase in the thrombotic events during the administration of 
TPOMs [27, 28]. Others, including those who analyzed larger patient groups, report 
a prothrombotic risk associated with this therapy in the a-PL positive subgroup 
[29–31]. Gonzales et al. found in their retrospective study of 46 patients with 
thrombocytopenia and various systemic autoimmune disorders, all treated with 
eltrombopag, that 3 (6.5%) participants suffered from thrombotic events while on 
treatment. Crucially, 6 out of 46 participants had concurrent APS, and 2 of them 
(33% of all patients with aPL) were among those with thrombosis [30]. Guitton 
et al. retrospectively studied 18 patients with thrombocytopenia and SLE treated 
with romiplostim or eltrombopag; 10 had been diagnosed with concurrent aPL/
APS. 5 patients developed thrombosis; 3 of them (30% of all patients with aPL) had 
APS [31]. These observations suggest a higher thrombotic risk in the aPL-positive 
group. Though well established in therapy of ITP, the use of TPOMs in aPL-positive 
patients requires caution and individual evaluation of thrombotic risk. Minimized 
dosing of TPOMs, aimed to maintain platelet count around 50000/μL, was sug-
gested to decrease thrombotic risk since the thrombotic events are more frequent at 
platelet count greater than 100000/μL [22].
Except for severe thrombocytopenia, a decrease in platelet count does not fully 
protect patients with aPL/APS from thromboembolic events, and antithrombotic 
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prevention or therapy should be continuing as long as possible. However, bleeding 
risk has to be considered, and an individualized approach is mandatory. In general, 
full anticoagulation can be given in the setting of platelet count over 50000/μL, 
and its stopping should be considered seriously in platelet count below 25000/
μL. The patients with platelets between these values should be treated individually 
with anticoagulants in reduced doses. Half-dose low molecular weight heparins 
(LMWHs) represent the usual first-choice treatment [22].
3. Factor deficiencies associated with aPL
3.1 Hypoprothrombinemia
Acquired deficiency of prothrombin, referred to as lupus anticoagulant hypo-
prothrombinemia syndrome, is the most known and well defined of all coagulation 
factor deficiencies associated with aPL. Its precise incidence is unclear, but with the 
order of magnitude of hundreds of reported cases, it appears to be a rare complica-
tion [32, 33]. It typically occurs in the child or adolescent female patients with aPL 
after viral infections or with systemic immune disorders, most commonly SLE [34]. 
Adults can be affected as well, albeit less frequently [35]. The preexisting systemic 
immune disease is not obligatory since cases without were identified; other precipi-
tating conditions include tumors such as lymphomas, particularly with the produc-
tion of pathological immunoglobulins and drug reactions.
Bleeding severity varies from mild mucocutaneous (epistaxis, ecchymosis), 
which is the most common, to severe and life-threatening, including localizations 
such as muscles, genitourinary tract, gastrointestinal tract (GIT), and central 
nervous system (CNS) [32–38]. A substantial number of patients (up to 50%) have 
no significant bleeding events and can be even asymptomatic [36]. Concomitant 
presence of thrombotic events, hemorrhagic-thrombotic syndrome, and CAPS were 
occasionally described [39–41]. The condition is usually self-limiting when associ-
ated with viral infections, whereas it can have a lasting duration or relapses in the 
presence of autoimmune diseases [36]. Despite the possibility of severe bleeding 
events, the overall prognosis is good in general, with a reported mortality rate of 
less than 5%.
Laboratory findings include the prolongation of both prothrombin (PT) and 
activated partial thromboplastin time (aPTT), variably decreased prothrombin 
activity (about 10–20% on average, although it may be extremely low or unmeasur-
able) with a proportional decrease of prothrombin antigen. As mentioned above, 
a deficiency of other coagulation factors might be present. Therefore, their activ-
ity should be checked [32]. Positive testing for LA complements the picture. The 
finding of PT prolongation in an aPL-positive patient should prompt the testing for 
prothrombin deficiency even if no bleeding is apparent at the time.
The traditional view based on the initial analyses in the 1980s defined the 
involved antibodies as non-neutralizing, unable to directly inhibit the prothrombin 
coagulation activity [42]. Cross-reactivity between the aPL and phospholipid epit-
opes in the prothrombin molecules is a likely explanation. The aPL form prothrom-
bin antigen–antibody complexes, and their subsequent elimination results in the 
proportional decrease of both prothrombin activity and antigen. If the clearance is 
extensive enough to lead to a relevant prothrombin decrease with its activity below 
20%, bleeding manifestations may occur. However, some researchers provided con-
flicting evidence with hints on more complex changes of hemostasis. In the recent 
analysis of a relatively large cohort of 41 patients, Japanese authors did not observe 
an exact correlation between prothrombin levels, anti-FII antibody quantity, and 
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bleeding phenotype. They also identify different autoantibodies directed against 
FVIII besides the anti-prothrombin ones in several patients with the disorder [43]. 
They confirmed combined coagulation factor deficiencies in a small number of the 
studied cases as well. Based on this observation and a known heterogeneity of the 
clinical presentation, it is reasonable to conclude that hypoprothrombinemia is not 
an isolated change in aPL-positive patients, and a complex evaluation of hemostasis 
is always required.
The therapeutic approach aims at (1) stopping the active bleeding; (2) eradicating 
antibodies responsible for prothrombin deficiency; (3) preventing further throm-
boembolic events [35, 37]. The withdrawal of antithrombotic agents, supplementa-
tion of blood components (transfusion of packed red blood cells and fresh frozen 
plasma), activation of coagulation factor production (vitamin K administration), 
hemostatic agents (styptics, antifibrinolytics) represent the strategies for bleeding 
cessation [35]. However, all these approaches can in aPL-positive patients, especially 
in prolonged use, lead to the increased thrombotic risk. Immunosuppression, with 
corticosteroids as the first-line choice or other agents (azathioprine, rituximab, 
cyclophosphamide) and procedures (plasma exchange) as alternatives, leads 
to antibody eradication. Monotherapy with corticosteroids is efficient in most 
cases. Measurement of prothrombin levels, whether by clotting, chromogenic or 
immunologic methods, can be used for the treatment monitoring. Since the risk of 
thrombosis usually remains significantly increased even in the presence of bleeding 
and bleeding itself does not protect from thromboembolism, the therapies aimed at 
bleeding cessation has to be counterweighted by antithrombotic therapy. Both bleed-
ing and thromboembolic risks have to be evaluated carefully in all cases.
3.2 von Willebrand factor deficiency (von Willebrand syndrome)
Few case reports of concurrent acquired von Willebrand syndrome (AWS), 
an acquired vWF deficiency, with the presence of aPL were described [44–48]. 
Interestingly, other disorders with well-defined relation to AWS (myeloproliferative 
neoplasm, aortic valve stenosis, connective tissue diseases such as SLE) were identi-
fied in most cases. Therefore, aPL are not regarded as a usual cause of AWS, but 
rather as a coincidental finding in underlying immune disorders. Some researchers 
speculated that aPL might modify and counterbalance the bleeding phenotype typi-
cal for AWS [44, 48]. Thrombotic event after normalization of vWF was reported 
[44]. Immunosuppression, the standard treatment of AWS, combined with anti-
thrombotic prevention, was given in reported cases with good clinical outcomes.
3.3 Deficiencies of other coagulation factors
Acquired deficiencies of other clotting factors, namely FVII, FVIII, FX, and 
FXI, were reported [49–52]. In summary, these deficiencies are extremely rare, and 
clinical data are limited to case reports or series. Bleeding manifestations are vari-
able, with varying severity. The therapeutic strategies are similar to the approach 
used in AWS.
4. Bleeding in thrombotic microangiopathies associated with aPL
4.1 Diffuse alveolar hemorrhage
DAH is a severe and life-threatening pulmonary complication of aPL. 
Inflammatory damage to the pulmonary microcirculation, namely to alveolar 
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arterioles, capillaries, and venules, with subsequent necrotic changes and second-
ary hemorrhage, define the disorder [53]. A microscopic pathoanatomical picture 
typically reveals capillaritis with interstitial neutrophilic infiltrate, thrombi in 
small muscular pulmonary arteries, myointimal thickening, and the remodeling of 
the muscular pulmonary arteries and arterioles [53, 54]. The condition is rare and 
appears in less than 1% of all aPL-positive patients, though it is considerably more 
frequent and clinically relevant in those with CAPS, affecting 5–10% [54–57]. Both 
genders are affected, but males constitute approximately 2/3 of cases with primary 
APS, whereas women dominate the group with APS secondary to SLE [54]. The 
patients with DAH are more likely to have a higher titer of aPL and suffer from 
other comorbidities associated with aPL than those without DAH. Cardiac valve 
disease, pulmonary hypertension, livedo reticularis, skin ulcers, CNS involvement 
(stroke or seizure), and pregnancy complications are among the reported concomi-
tant disorders [54, 57].
Several pathomechanisms are likely to participate in the damage of the alveolar 
structures in DAH in aPL-positive patients. aPL-mediated activation of endothelial 
cells, resulting in the increased expression of tissue factor, platelet, and comple-
ment activation with C5a-mediated neutrophil recruitment and the subsequent 
lung tissue injury is likely behind thrombi formation in the pulmonary microcircu-
lation. aPL-induced systemic inflammatory response syndrome with the excessive 
cytokine activation (e. g. tumor necrosis factor-α, interleukin-1, interleukin-6, 
interleukin-18, macrophage migration inhibitory factor) as well as L-ficolin-
induced lung injury and interstitial neutrophilic infiltration lead to the loss of the 
integrity of the alveolar-capillary basement membrane. Disruption of alveolar 
structure and its veins through the combination of inflammation and thrombosis 
result in the extravasation of red blood cells into the alveoli [58].
The usual clinical presentation of DAH includes fever, chest pain, cough with 
hemoptysis, and dyspnea with the signs of hypoxemic respiratory failure [4]. 
However, not all symptoms, including hemoptysis, need to be present in every 
case. The symptoms are not specific and appear in other pulmonary diseases such 
as pulmonary embolism, pneumonia, and pulmonary edema. The complex dif-
ferential diagnostics is of utmost importance. Laboratory and complementary 
tests are critical for the distinction of DAH. Anemia, aPL positivity, high diffusing 
capacity for carbon monoxide in pulmonary function tests, patchy or perihilar 
opacities on the chest X-ray and signs of hemorrhage, ground-glass infiltrates, and 
reticular interstitial opacities on pulmonary CT scans belong to the typical find-
ings. Bronchoscopy with bronchoalveolar lavage and biopsy can document alveolar 
hemorrhage, exclude infections, and provide biological material for cytologic and 
histologic evaluation. Lung biopsy remains the gold standard for the definitive 
diagnosis, albeit the patient′s condition and benefit–risk ratio should be evaluated 
before the procedure. As mentioned above, DAH is quite frequently associated with 
CAPS. Treating physicians should actively search for its signs in all cases.
Immune suppression remains the mainstay of the therapy. High-dose cortico-
steroids are the preferred initial treatment. The use of other immunosuppressives 
remains without a clear consensus due to the rarity of the condition and limited 
clinical data. However, available clinical data support the combined immune sup-
pression (corticosteroids plus another immunosuppressive agent) over monotherapy 
with corticosteroids. The combined therapy seems to improve the clinical outcome 
and rate of long-term remission. Cyclophosphamide and rituximab have been show-
ing encouraging results, whereas mycophenolate mofetil and azathioprine seem to 
be less effective [4]. Other therapeutic modalities that could be beneficial, especially 
in the presence of underlying CAPS, include plasma exchange and IVIg.
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4.2 Adrenal hemorrhage
AH is a potentially devastating complication of aPL due to the resulting adre-
nal insufficiency. AH represents an infrequent cause of adrenal insufficiency, 
and besides aPL, it can be caused by other disorders, namely adrenal tumors and 
anatomical malformations, infections, and bleeding disorders (thrombocytopenia, 
heparin exposure) [59]. AH is a rare complication of aPL with its prevalence not 
precisely established. However, a significant proportion - one third - of affected 
patients have CAPS. The incidence in this subgroup is thus relatively high, between 
10 to 16% [56]. A provoking moment usually initiates aPL-induced AH. Trauma, 
invasive procedures, infections, and warfarin withdrawal have been identified as 
such moments [60].
The main pathomechanism in aPL-induced AH, supported by the autopsy 
evidence, is multiple thromboses in the adrenal plexus leading to the secondary 
hemorrhage and destruction of the adrenal cortex. Due to its unique vascular 
anatomy (complex arterial system with three supplying arteries, rich vascular 
plexus in the zona reticularis, single drainage vein), the adrenal gland is prone to 
develop intraparenchymal hemorrhage in a case of venous obstruction. Vasculitis 
has not been found in aPL-induced AH [61].
AH usually manifests with back pain. Symptoms related to acute adrenal insuffi-
ciency (hypotension, malaise, fever, altered mental status, gastrointestinal symp-
toms including nausea, vomiting, and diarrhea) complement the clinical picture. 
Apart from the chronic adrenal insufficiency, skin hyperpigmentation is not present 
in the aPL-induced AH [59].
Laboratory tests and radiological imagining studies are critical for the confirma-
tion of AH. Decreased cortisol levels and the lack of increase in cortisol levels after 
an adrenocorticotropic hormone stimulation test represent a typical laboratory 
finding. Abdominal contrast CT is the standard imagining method. However, CT 
has its limits, and if performed in the early phases of the bleeding, it may be falsely 
negative. A repeated CT scan is a must in the case of high clinical suspicion despite 
an initial negative result. Abdominal magnetic resonance is an alternative imagin-
ing method with the best imaging of the adrenal glands [62]. If the laboratory and 
imaging studies are inconclusive, adrenal biopsy remains the definitive diagnostic 
procedure. However, it is a high-risk procedure in terms of bleeding, and the 
risk–benefit ratio has to be evaluated individually. As a general rule, adrenal biopsy 
should be avoided in aPL-positive patients.
Clinical management has two goals: 1) to provide substitution of adrenal 
hormones, especially glucocorticoids; 2) to prevent further complications of 
aPL, namely thromboembolism. Since CAPS is a frequent finding in aPL-positive 
patients with AH, antithrombotics should be administered as long as possible 
despite hemorrhage. If their withdrawal is necessary, usually due to the extensive 
bleeding, the restart should be as soon as possible. The clinical experience stresses 
the critical importance of antithrombotic therapy. The study with aPL-positive 
patients and AH observed concurrent thrombotic events during the acute phase 
in 7 (43%) out of 16 participants. Five of 7 patients with confirmed thrombosis 
were diagnosed with CAPS [60]. Apart from the glucocorticoid substitution due 
to adrenal insufficiency, immunosuppressives are not a standard part of treatment 
since the available evidence does not confirm an effect on the clinical outcome [61]. 
However, their addition, alone or in combination with IVIg and plasma exchange, 
can be beneficial in the presence of CAPS.
The long-term prognosis of AH is relatively favorable after the acute phase, 
especially if antithrombotics are uninterrupted. In a review of 62 patients with AH 
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followed for a mean of 25 (2–60) months, 90% (32 out of 35) of anticoagulated 
patients survived. Interestingly, overall mortality in the study reached 36% (25 out 
of 69 participants) [61]. Adrenal dysfunction is irreversible in most cases, although 
occasional recovery remains possible.
4.3 Catastrophic antiphospholipid syndrome
CAPS represents the most severe and potentially fatal variant of APS. It is 
characterized by excessive activation of hemostasis, rapid, multiple, and progres-
sive thrombotic events, typically affecting small vessels, resulting in acute multiple 
organ dysfunction (usually kidneys, lungs, CNS, heart, skin) and TMAs [63]. 
Fortunately, CAPS is a relatively infrequent complication, affecting approximately 
1% of patients with APS [2]. CAPS is the first manifestation of previously unrec-
ognized or newly formed aPL in up to 50% of patients [10]. However, it can be the 
complication of preexisting and known aPL or APS as well. Its onset is usually - in 
about 2/3 of cases - related to precipitating factors such as infections, malignancies, 
trauma, invasive procedures, activation of underlying autoimmune disease, preg-
nancy complications, certain medications (oral contraceptives), and withdrawal 
or inadequate antithrombotic therapy. Pathological complement activation plays a 
critical role in its development [64].
Thromboembolic events and their complications dominate the clinical picture. 
Bleeding is typically secondary to the initial thromboembolism, although rarely can 
be among the initial clinical manifestations [65, 66]. The etiology of hemorrhage 
in CAPS is complex. It involves thrombocytopenia secondary to excessive platelet 
activation and consumption, consumption of coagulation factors, endothelial 
damage and dysfunction, thrombocytopenic thrombotic purpura (TTP)-like 
hemostatic changes, and development of DIC [67, 68]. Thrombocytopenia is a 
dominant change in CAPS, affecting up to 40% of patients with the complication. 
Thrombocytopenia, mainly if it manifests as the acute drop in platelet count in 
patients with aPL/APS and previously normal platelets, can be the first sign of 
impeding CAPS and precede the full clinical picture of CAPS for several days [11]. 
TTP-like changes frequently accompany thrombocytopenia [68]. Clinical presenta-
tion of hemorrhage is variable, with every organ system being a possible target. 
Life-threatening hemorrhage, including bleeding in the CNS and GIT, can occur 
[65, 66]. As mentioned before, DAH and AH are relatively frequent complications 
of CAPS.
The therapeutic approach is aggressive with several goals: 1) to suppress the 
immune system and production of aPL; 2) to prevent and treat thromboembolic 
events; 3) treat the underlying or provoking disorder. The combined immunosup-
pressive and immunomodulatory therapy (corticosteroids, IVIg, plasma exchange) 
together with full anticoagulation (preferably with heparin or LMWHs in the acute 
phase with the transition to warfarin) represents the initial therapeutic step [63]. 
Cyclophosphamide is the preferred immunosuppression in patients with underlying 
SLE. Rituximab and eculizumab are novel therapeutic possibilities that seem to be 
efficient in patients with predominant hematologic or microthromboangiopathic 
manifestations or resistant to first-line treatment [63, 69, 70]. Despite aggressive 
treatment and novel agents, the prognosis remains unfavorable in a significant 
number of cases, with a mortality rate reaching up to 40% [2]. The individual 
assessment of thrombotic and bleeding risk is an indispensable part of therapeutic 
management. The continuation of antithrombotic therapy is preferred over its 
tapering or withdrawal. Its continuation has to be considered even in the presence 
of hemorrhage.
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5. Bleeding associated with antithrombotic agents
Bleeding events, particularly those involving the CNS and GIT, are regarded 
as potentially serious, but the expected adverse events of antithrombotic therapy. 
The incidence of major bleeding ranges from 3 to 6 per 100 person-years depend-
ing on the anticoagulant. It is high for patients on warfarin in particular [71]. The 
incidence of bleeding on antiplatelet therapy is generally lower, 3 to 4 per 1000 
person-years [72]. The risk increases with the intensity of treatment or concomitant 
use of several agents. The combination of the anticoagulant with antiplatelet agent 
increases the risk of bleeding approximately 1.5 to 2-fold in comparison to antico-
agulant therapy alone [73].
Since the presence of aPL represents a high-risk thrombophilia, antithrombot-
ics – anticoagulants, antiplatelet agents, or their combination - are administered 
for a prolonged period, frequently life-long in most aPL-positive patients. The 
continuous administration of antithrombotic agents is used even in asymptomatic 
individuals with estimated high prothrombotic risk. Warfarin remains the preferred 
agent for anticoagulation, with the intent to achieve a higher INR range of 3.0–4.0 
in specific clinical situations (recurrent thrombotic events, arterial events) [74].
Based on the current clinical practice and preferred intensity of therapy, aPL-
positive patients receiving antithrombotics may seem to have an increased risk of 
treatment-related bleeding. However, available data show that hemorrhage does 
not represent the main clinical issue. The mortality rate due to thrombosis and its 
recurrence remains several times higher than the mortality rate related to bleeding. 
For example, a review of clinical studies documented 18 deaths related to recurrent 
thrombosis and only one due to hemorrhage [75]. The analysis of a prospective 
10-year follow-up of 1000 patients with APS, performed as a part of the Euro-
Phospholipid project, identified 34 deaths attributed to thromboembolism and only 
10 to bleeding [76]. Reviews of clinical studies focused on anticoagulant therapy in 
APS suggest that, if INR on warfarin is within the standard therapeutic range, the 
major bleeding does not appear to be significantly more frequent in comparison to 
other patient groups on warfarin and is about 1.5–2.0% per year [77]. If higher INR 
levels (3.0–4.0) are needed, the risk of bleeding, but predominantly mild, increases 
significantly, approximately 2 to 2.5 times [77, 78]. As for antiplatelet agents, the 
rate of bleeding during their prophylactic or therapeutic use appears to be low, 
and major bleeding is rare [78, 79]. The risk of bleeding increases after invasive 
procedures, likely due to the use of bridging therapy, the early reintroduction of 
antithrombotics, and aggressive antithrombotic policies [80, 81]. Then again, 
thrombotic risk after surgery increases considerably as well despite preventive 
measures.
Independent predictors of major bleeding include overdose with warfarin (e. 
g. INR above 4.0), combined antithrombotic therapy, polypharmacy, age over 
75 years, history of major bleeding (mostly gastrointestinal), malignancy, uncon-
trolled arterial hypertension, leukoaraiosis, and patient non-compliance [76–78]. 
It is critical to evaluate individual bleeding and prothrombotic risk and purposely 
identify potential risk factors. Caution is especially required when high-intensity 
anticoagulation or a combination of antithrombotics are indicated.
6. Conclusion
Bleeding is a rare but potentially severe complication of aPL and APS. Its 
etiology is heterogeneous; aPL-positive patients can develop bleeding due to 
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thrombocytopenia, acquired coagulation factor deficiencies (predominantly hypo-
prothrombinemia), TMAs, or the adverse events of antithrombotic therapy (mostly 
with warfarin). However, thromboembolic events represent the most dangerous 
complications for aPL-positive patients, and the thrombotic risk remains clinically 
relevant even in the presence of hemorrhage in the majority of patients.
The management of bleeding is challenging. It is necessary to balance both 
thrombotic and bleeding stimuli and to continue antithrombotic prevention or ther-
apy for as long as possible. The individual approach is critical for a favorable clinical 
outcome. Specific treatment can be necessary for eliminating the cause of bleeding 
and achieving its control. Immunosuppressive agents, especially corticosteroids, 
are the first-choice treatment for aPL-associated thrombocytopenia, coagulation 
factor deficiencies, CAPS, and DAH. Other immunosuppressive or immunomodu-
latory agents can be efficient in case of unsatisfactory clinical response. Rituximab 
appears to be the most promising alternative. Corticosteroids are also fundamental 
for the diffuse alveolar hemorrhage, albeit firstly for the correction of consequential 
adrenal insufficiency. aPL-positive patients receiving antithrombotics should be 
monitored closely, and their compliance ensured, especially in the scenario with the 
high-intensity or combined antithrombotic therapy.
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